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Abstract
Background. Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases 
in China. It is usually asymptomatic and transabdominal ultrasound (USS) is the usual means for 
diagnosis, but it may not be feasible to have USS screening of the whole population.
Objective. To develop a risk scoring model for predicting the presence of NAFLD using parameters 
that can be easily obtain in clinical settings.
Methods. A retrospective study on the data of 672 adults who had general health check including 
a transabdominal ultrasound. Fractional polynomial and multivariable logistic regressions of 
sociodemographic and biochemical variables on NAFLD were used to identify the predictors. 
A risk score was assigned to each predictor using the scaled standardized β-coefficient to create 
a risk prediction algorithm. The accuracy for NAFLD detection by each cut-off score in the risk 
algorithm was evaluated.
Results. The prevalence of NAFLD in our study population was 33.0% (222/672). Six significant 
factors were selected in the final prediction model. The areas under the curve (AUC) was 0.82 (95% 
CI: 0.78–0.85). The optimal cut-off score, based on the ROC was 35, with a sensitivity of 76.58% 
(95% CI: 70.44–81.98%) and specificity of 74.89% (95% CI: 70.62–78.83%).
Conclusion. A NAFLD risk scoring model can be used to identify asymptomatic Chinese people 
who are at risk of NAFLD for further USS investigation.
Key words:  Chronic disease, obesity, primary care, risk assessment, screening.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a liver disease that 
may progress to liver cirrhosis and hepatocellular carcinoma. In 
Asia, the prevalence of NAFLD ranges from 5% to 40% (1), with 
China being one of the high prevalence countries. With the changes 
in diet structure and lifestyle, the prevalence of NAFLD is increasing 
in developing countries including China, especially in big cities (2). 
Its threat to the health of the Chinese population is only second to 
hepatitis. NAFLD is associated with insulin resistance condition and 
can represent a hepatic manifestation of the metabolic syndrome 
(MS) which comprises obesity, dyslipidemia, hypertension and glu-
cose intolerance (3). In recent years, studies show that simple hepatic 
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steatosis may progress to non-alcoholic steatohepatitis (NASH) and 
fibrosis if the weight and abdominal circumference increase. Weight 
loss may reduce the occurrence of hepatic complications (4). Early 
detection and treatment may reverse the progression of the disease. 
It is very important to detect NAFLD early so to control the risk fac-
tors through health education and lifestyle intervention to reduce the 
incidence of NAFLD and its complications.
Most NAFLD are asymptomatic in the early stage and are 
detected as an incidental finding during imaging examination for 
other diseases or health assessment. In many cases, the first sign of 
illness does not occur until significant liver damage has developed. 
Symptoms typically include fatigue, nausea, abdominal discomfort, 
jaundice, etc. The use of liver function tests such as alanine ami-
notransferase (ALT) or aspartate aminotransferase (AST) alone are 
not reliable. Studies in the United States revealed good associations 
between metabolic parameters and the presence of NAFLD (5,6).
Transabdominal ultrasound is a simple, widely available, accept-
able and accurate for the diagnosis of fatty liver (7), but it may not 
be feasible or cost-effective for population screening. Therefore, it is 
useful to identify people at high risk of NAFLD base on metabolic 
risk factors and sociodemographic factors.
The aim of this study was to develop a risk scoring model for 
predicting the presence of NAFLD using parameters that can be eas-
ily obtain in clinical settings.
Methods
Study subjects
The study design was a retrospective analysis of data of anonymized 
adults collected in routine health assessments in the Health Assessment 
and Management Center of the University of Hong Kong-Shenzhen 
Hospital from 1 January 2014 and 31 March 2014. According to the 
guidelines for diagnosis of NAFLD in China (8), inclusion criteria 
were adults aged more than 18 years. Exclusion criteria were regular 
drinkers (alcohol intake ≥3 times per week) at any level (9), patients 
with history of viral hepatitis, including carriers hepatitis B or hepa-
titis C, drug-induced liver disease, total parenteral nutrition, hepato-
lenticular degeneration, and autoimmune liver disease.
Study methods
A comprehensive health assessment was conducted in all subjects as 
following: a questionnaire was used to obtain information on age, 
gender, frequency of alcohol intake (how many times per week), 
smoking status and medical history, when the subjects had difficulty 
completing the questionnaire, trained nurses provided assistance. 
Height and body weight were measured in subjects wearing light 
clothing without shoes, body mass index (BMI) was calculated as 
body weight in kilograms divided by the square of height in meters. 
The measurement of waist circumference was done by trained 
nurses. The average of the blood pressure (BP) measurements was 
recorded after BP was measured twice on the right arm of the seated 
subjects with an electronic sphygmomanometer, BP included systolic 
blood pressure (SBP) and diastolic blood pressure (DBP). In addi-
tion to a transabdominal ultrasound of the liver, and tests on serum, 
uric acid (UA), total cholesterol (TC), triglyceride (TG), high density 
lipoprotein (HDL), low density lipoprotein (LDL), haemoglobin A1c 
(HbA1C), fasting glucose, ALT and AST were done. Venous blood 
samples were collected following an overnight 8 hours of fasting. 
UA, TC, TG, HDL, LDL, fasting glucose, ALT and AST levels were 
measured using the Roche Cobas 8000 chemistry analyzer. HbA1C 
was measured by the high performance liquid chromatography 
(HPLC) method using ADAMSTMA1c HA-8160.
Diagnosis of fatty liver
For the purpose of this study, the ‘gold standard’ for diagnosing 
fatty liver was transabdominal ultrasound. Fatty liver was diag-
nosed, if at least two of three abnormal findings were present on 
USS: diffusely increased echogenicity that is greater than the kidneys 
or spleen, vascular blurring, or deep attenuation of ultrasound sig-
nal (10). Ultrasound examination was done using PHILIPS HD15 
equipped with a convex 3.5 MHz probe, performed by one of two 
experienced and professional ultrasound doctor in the University 
of Hong Kong-Shenzhen Hospital, who were blinded to patients’ 
blood test results.
Risk factors
According to previous literatures (11–13), the NAFLD risk fac-
tors in this study were used as following: age, gender, metabolic 
risk factors including overweight (BMI ≥25 kg/m2), central obesity 
(waist circumference  ≥90  cm for men and  ≥80  cm for women), 
raised blood pressure (SBP  ≥130  mmHg or DBP  ≥85  mmHg), 
hyperuricemia (UA >428  µmol/L for men and >357  µmol/L for 
women), hypertriglyceridemia (TG  ≥1.7  mmol/L), reduced HDL 
(HDL <1.03 mmol/L for men and <1.29 mmol/L for women), raised 
fasting glucose (fasting glucose  ≥6.1  mmol/L), Hyperglycemia 
(HbA1c ≥6.5%).
Table  1. Demographic and clinical characteristics of patients 
(N = 672)
Characteristics Total samples (n = 672)
Sociodemographic
 Age (years), mean ± SD (range) 47.2 ± 9.6 (27.0–82.0)
 Gender (%, n)
  Female 18.5% (124)
  Male 81.5% (548)
Clinical parameters (%, n)
 BMI (kg/m2)
  <25 62.8% (422)
  ≥25 37.2% (250)
 Waist circumference (cm)
  Male <90, Female <80 59.7% (401)
  Male ≥90, Female ≥80 40.3% (271)
 Blood pressure (mmHg)
  SBP < 130 & DBP < 85 61.5% (413)
  SBP ≥ 130 or DBP ≥ 85 38.5% (259)
 Uric Acid (µmol/L)
  Male ≤428, Female ≤357 67.3% (452)
  Male >428, Female >357 32.7% (220)
 Triglyceride (mmol/L)
  <1.7 66.1% (444)
  ≥1.7 33.9% (228)
 HDL (mmol/L)
  Male ≥ 1.03, Female ≥ 1.29 69.5% (467)
  Male < 1.03, Female < 1.29 30.5% (205)
 Fasting glucose (mmol/L)
  <6.1 90.9% (611)
  ≥6.1 9.1% (61)
 HbA1c (%)
  <6.5 94.2% (633)
  ≥6.5 5.8% (39)
 Fatty liver
  Absence 67.0% (450)
  Presence 33.0% (222)
BMI, Body mass index; SBP, Systolic blood pressure; DBP, Diastolic blood 
pressure; HDL, High Density Lipoprotein; HbA1c, Haemoglobin A1c.
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Data analysis
All subjects with missing data were excluded from the analysis. The 
continuous variable was age; other collected data on the risk fac-
tors were transformed into categorical variable: gender (male and 
female), BMI (<25 and ≥25 kg/m2), waist circumference (male <90 
and ≥90 cm; female <80 and ≥80 cm), SBP (<130 and ≥130 mmHg), 
DBP (<85 and  ≥85  mmHg), UA(male ≤428 and >428  µmol/L; 
female ≤357 and >357 µmol/L), TG (<1.7 and ≥1.7 mmol/L), HDL 
(male ≥1.03 and <1.03 mmol/L; female ≥1.29 and<1.29 mmol/L), 
fasting glucose (<6.1 and ≥6.1 mmol/L), HbA1c (<6.5 and ≥6.5%).
Descriptive data analysis and model development
Descriptive statistics were performed on the characteristics of sub-
jects. Age was handled using fractional polynomial, other risk fac-
tors were entered into samples using stepwise logistic regression 
model. Significant risk factors with P < 0.05 were selected to pro-
duce a final assessment model. Both forward selection and backward 
selection were used to see if selected predictors were consistent. Each 
factor in the final model was assigned a weighted risk score using its 
β-coefficient divided by its standard error. All standardised scores 
were scaled up to construct a risk algorithm with a maximum of 100 
points. Youden’s J statistic (14) was used to determine the optimal 
cut-off point that yields the best sensitivity and specificity.
Model diagnostics
The discrimination of the risk algorithm was evaluated with the 
receiver operating characteristics (ROC) curve with 95% CI, cali-
bration was assessed by Hosmer and Lemeshow statistic in which 
an insignificant value indicates a good fit. Calibration was also 
inspected via calibration plot.
Results
Characteristics of the study subjects
Data were collected on a total of 674 patients. Two patients with 
missing data were excluded from the analysis. The prevalence of 
overweight, central obesity, raised blood pressure, hyperuricemia, 
hypertriglyceridemia, reduced HDL, raised fasting glucose, hyper-
glycemia and fatty liver disease were 37.2% (250/672), 40.3% 
(271/672), 38.5% (259/672), 32.7% (220/672), 33.9% (228/672), 
30.5% (205/672), 9.1% (61/672), 5.8% (39/672) and 33.0% 
(222/672), respectively (Table 1).
Multivariate analysis and model development
Based on the fractional polynomial comparisons testing the best 
fractional polynomial models for age, the effect of age was insig-
nificant; therefore, age was left out in the list of predictors consid-
ered in regression model. Other factors were entered into stepwise 
logistic regression model. Fatty liver showed a correlation with 
overweight (OR: 2.31, 95% CI: 1.46–3.67), central obesity (OR: 
3.43, 95% CI: 2.16–5.45), hyperuricemia (OR: 2.07, 95% CI: 
1.39–3.08), hypertriglyceridemia (OR: 1.83, 95% CI: 1.18–2.82), 
reduced HDL (OR: 1.78, 95% CI: 1.15–2.76) and raised fasting 
glucose (OR: 3.24, 95% CI: 1.70–6.16) (Table  2). These signifi-
cant factors were selected for the final prediction model. The risk 
score assigned to each predictor using the scaled standardised 
β-coefficient is shown in Table  2. The Youden’s J statistics sug-
gested an optimal cut-off of 35 points. The sensitivity was 76.58% 
(95% CI:70.44–81.98%) and the specificity was 74.89% (95% 
CI:70.62–78.83%) when patients with risk score ≤ 35 are classified 
as disease-free (Table 3). The cut-off scores below 35 had higher 
sensitivity but lower specificity. While the cut-off scores above 
35 had lower sensitivity but higher specificity (Supplementary 
Table S1).
Model performance and internal validation
The AUC of the risk prediction model was 0.82 (95% CI: 0.78–
0.85) (Figure  1), and the Hosmer and Lemeshow statistic was 
insignificant (P = 0.77). Diagnostics performance was comparable 
with the sensitivity and specificity at an acceptable level (Table 3). 
The calibration plot of prediction models also performed well 
(Figure 2).
Table 2. Significant risk factors for predicting non-alcoholic fatty liver disease in total samples (N = 672)
Risk factors Odds ratio 95% CI P value β-coeff. Standard error Std. β-coeff. Assigned score
BMI (kg/m2)
 <25 1.00 — — — — — 0
 ≥25 2.31 1.46–3.67 <0.001* 0.84 0.24 3.50 17
Waist circumference (cm)
 Male <90, Female <80 1.00 — — — — — 0
 Male ≥90, Female ≥80 3.43 2.16–5.45 <0.001* 1.23 0.24 5.13 24
 Uric Acid (umol/L)
 Male ≤428, Female ≤357 1.00 — — — — — 0
 Male >428, Female >357 2.07 1.39–3.08 <0.001* 0.73 0.20 3.65 17
Triglyceride (mmol/L)
 <1.7 1.00 — — — — — 0
 ≥1.7 1.83 1.18–2.82 0.006* 0.60 0.22 2.73 13
HDL (mmol/L)
 Male ≥1.03, Female ≥1.29 1.00 — — — — — 0
 Male <1.03, Female <1.29 1.78 1.15–2.76 0.010* 0.58 0.22 2.64 12
Fasting glucose (mmol/L)
 <6.1 1.00 — — — — — 0
 ≥6.1 3.24 1.70–6.16 <0.001* 1.18 0.33 3.58 17
CI, Confidence interval; β-coeff., β-coefficient; Std. β-coeff., Standardised β-coefficient; BMI, Body mass index; HDL, High density lipoprotein.
*Significant with P value < 0.05.
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Discussion
Main findings
Our results demonstrated that fatty liver was more likely among 
people with overweight, central obesity, hyperuricemia, hypertriglyc-
eridemia, reduced HDL and raised fasting glucose. The combination 
of these easily measurable factors provides clinicians with a practical 
non-invasive tool to identify primary care patients at high risk of 
fatty liver, with adequate sensitivity and specificity of 76.58% and 
74.89%, respectively. The sensitivity and specificity are comparable 
to many commonly used clinical tests. The prevalence of fatty liver 
in our study population was 33.0%, which was higher than those 
observed in previous local studies 30.75% (15). The prevalence of 
NAFLD reported in Guangzhou in 2003 and Shanghai in 2005 
was 16.3% (16) and 15.4% (17), respectively, with an increasing 
prevalence of up to 20.5% in Guangzhou in 2008 (18), 27.3% in 
Hong Kong with the use of MRI in 2012 (19). The higher prevalence 
detected in this study may be related to the patients’ selection criteria. 
Firstly, people attending our Health Assessment and Management 
Center comprise mainly those who are more affluent in our society. 
Among our study subjects 37.2% were overweight and 40.3% were 
central obesity, thereby biasing towards a higher NAFLD prevalence 
in our study population. The factors associated with NAFLD found 
in this study are consistent with those reported in the literature. The 
‘two-hit’ model suggests the development of steatohepatitis due to 
insulin resistance with subsequent hepatocellular inflammation and 
fibrosis. Obesity plays a role in insulin resistance and hence hyper-
insulinaemia. Indeed, previous studies have a positive association 
between high fasting insulin levels and NAFLD. Insulin resistance 
also increases urate production (20) and excretion (21), explain-
ing the positive relationship between hyperuricemia and increased 
NAFLD found in our study. Hypertriglyceridemia is an important 
factor in the development of NAFLD (22), since excessive triglycer-
ide uptake can result in hepatocyte apoptosis. Hepatocellular injury 
from NAFLD inhibits hepatic glucose metabolism, which in turn 
raises serum glucose levels, contributing to the association between 
NAFLD and serum glucose (23).
A study of NAFLD scoring system development among adult 
medical check-up patients was held in Indonesia (24). Its prevalence 
of NAFLD was 51.0% higher than our study 33.0%. Its six inde-
pendent risk factors for predicting fatty liver were male, age, BMI, 
triglyceride levels, HDL, and serum ALT levels which differed from 
our final predictors. In the USA, a study compared the performance 
of four NAFLD prediction scores: fatty liver index, hepatic steatosis 
index, lipid accumulation product, and NAFLD liver fat score (LFT). 
LFT included AST/ALT ratio, diabetes, fasting AST level, fasting 
insulin level, and metabolic syndrome. They found that LFT was the 
best non-invasive prediction score for NAFLD in the US population 
(6). Therefore, those two NAFLD prediction methods may not be 
suitable for the Chinese population. Another model for predicting 
NAFLD in a Chinese population named ZJU index was developed 
based on BMI, fasting serum glucose, TG and ALT/AST ratio (25). 
Its predictors were different from our risk scoring model and it per-
formed better in subjects younger than 40 years old. ZJU index may 
also be helpful for distinguishing NASH from simple steatosis.
Implications for clinical practice
The screening tool derived from our results utilises six easily obtain-
able parameters (namely BMI, waist circumference, uric acid, triglyc-
eride, HDL and fasting glucose) to predict the presence of NAFLD 
with good sensitivity and specificity. Various cut-off scores had dif-
ferent sensitivities and specificities. The optimal cut-off score was 
35. The cut-off scores below 35 had higher sensitivity but lower 
specificity. While the cut-off scores above 35 had lower sensitiv-
ity but higher specificity. If a higher sensitivity is needed, we can 
choose a lower cut-off score for NAFLD prediction. Conversely, if 
a higher specificity is needed, a higher cut-off score can be chosen. 
Although our tool cannot diagnose NAFLD with absolute precision, 
its ease of use provides primary care physicians with a convenient 
and practical method for identifying patients at high risk for further 
investigation. At the same time, we can target personalised advice to 
patients who have high risk factors. For example, a 50-year old man, 
BMI = 25 kg/m2, WC = 90 cm, UA = 410 μmol/L, TG = 2.0 mmol/L, 
HDL = 0.9 mmol/L, fasting glucose = 5.8 mmol/L. According to the 
risk scoring model, calculate the score of each factors, BMI  =  17 
points, WC = 24 points, UA = 0 points, TG = 13 points, HDL = 12 
points. All scores were summed up to obtain the total score of 66 
points which was more than the optimal cut-off score 35. So, we 
could consider that this man probably had NAFLD.
Table 3. Discrimination and accuracy of risk model
Risk predication  
model (n = 672)
Accuracy (Using optimal cut-off value)
 Optimal cut-off score (range) 35 (0–100)
 AUC (95% CI) 0.82 (0.78–0.85)
 Sensitivity (95% CI) 76.58% (70.44–81.98%)
 Specificity (95% CI) 74.89% (70.62–78.83%)
 Positive predicted value (95% CI) 60.07% (55.80–64.19%)
 Negative predicted value (95% CI) 86.63% (83.55–89.21%)
 Positive likelihood ratio (95% CI) 3.05 (2.56–3.63)
 Negative likelihood ratio (95% CI) 0.31 (0.25–0.40)
Discrimination
 Hosmer and Lemeshow Test 0.77
AUC, Area under the curve; CI, Confidence interval.
Figure 1. Receiver Operating characteristics curve of the risk scoring model 
(N = 672)
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Strengths and limitations
Patients were assessed using a uniform protocol with USS conducted 
by a restricted number of doctors to reduce reporting bias. Although 
USS is not the most accurate diagnostic tool for NAFLD and may not 
be able to detect very early stages of the diseases, we believe that it is 
adequate from a clinical perspective. Another limitation in this study 
is that we have not considered dietary factor (26), which may con-
tribute to NAFLD. Nevertheless, quantifying diet and translating it 
into a screening tool may not be practical from a clinical perspective. 
The model is also susceptible to the issue of overfitting, as there is no 
cross-validation performed. The model will require validation with 
other dataset to ensure its validity. Finally, our results may not be 
generalizable to other populations in China since our subjects were 
healthy adults living in urban areas. Again, validation among other 
primary care populations will be required to confirm its accuracy.
Conclusion
In conclusion, a NAFLD risk prediction scoring model consisting 
of BMI, waist circumference, uric acid, triglyceride, HDL and fast-
ing glucose can be used to identify people who are at high risk of 
NAFLD for further USS investigation, and it rare the resource for 
unnecessary tests in adults at low risk especially in primary care 
institutions. In this study, the results show that the model has good 
sensitivity and specificity for predicting NAFLD, it can be widely 
used in the future.
Supplementary Material
Supplementary data are available at Family Practice online.
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